SIRT5

Across TCGA pan-cancer cohorts, SIRT5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIRT5 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SIRT5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SIRT5 expression acts as an unfavorable survival marker, although some lineages such as COAD and CCRCC show a favorable association.

COAD, LUAD, and LSCC are the cancer types where SIRT5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.921	.015	24	view →
LUAD	OS	Median	All	0.613	0.844	.028	8	view →
LSCC	DFS	Quartile	All	0.366	0.812	.022	3	view →
CCRCC	DFS	Tertile	III,IV	0.723	0.300	.034	3	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIRT5–COAD (DFS)

Open the COAD breakdown →